Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor
This study tests a new weekly combination medicine called CagriSema to see how well it helps adults with type 2 diabetes lower their blood sugar and body weight. Researchers want to find out if taking these two medications together works better than taking them separately or taking an inactive dummy medicine.
You may be able to join if you are 18 or older, have been diagnosed with type 2 diabetes for at least 180 days, and take metformin with or without an SGLT2 inhibitor. Participants must also meet specific blood sugar levels and not have severe kidney disease.
Participants will take a once-weekly injection under the skin along with their usual diabetes medications. You will be compared against groups taking single medications or a dummy medicine to see how your blood sugar and weight change.
This study has locations in places like Birmingham and Pelham, Alabama. The study is currently completed, meaning participants have already finished their trial visits.
- 1Tests the new combination medicine CagriSema for type 2 diabetes.
- 2Compares the combination against single medications and a dummy treatment.
- 3Focuses on improving blood sugar control and supporting weight loss.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.